Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Related documents

• Habit not heredity: central banks and global order#248006
• Risk of premature death from tobacco smoking, alcohol, and social inequalities in urban India#248007
• Business model innovation for disruptive sustainability: a theorizing review on how interdependencies between business model components reshape the problem-solution nexus#248008
• How far does regulation determine how for-profit welfare services operate?#248009
• Rhyme words in English love lyric 1300–1579#248010